Business Context and Reporting Period
Company: Apimeds Pharmaceuticals US, Inc. (APUS)
Reporting Period: Quarter and six months ended June 30, 2025
Business Overview: A clinical-stage biopharmaceutical company developing Apitox, a bee venom-based therapeutic for osteoarthritis and multiple sclerosis. The company operates as a single segment and has not yet generated revenue.
Key Event: Consummated an Initial Public Offering (IPO) on May 12, 2025, selling 3,375,000 shares at $4.00 per share.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(2,662,193) | $(3,064,590) |
| Loss Per Share (Basic & Diluted) | $(0.26) | $(0.33) |
| Cash and Cash Equivalents (End of Period) | $8,735,323 | $8,735,323 |
| Total Assets | $10,546,681 | $10,546,681 |
| Total Liabilities | $809,002 | $809,002 |
| Shareholders' Equity | $9,737,679 | $9,737,679 |
| Operating Cash Flow (Six Months) | $(3,381,409) | |
| Financing Cash Flow (Six Months) | $12,126,646 |
Material Changes vs. Prior Period
- Revenue: Remained at $0, consistent with the prior period.
- Net Loss: Increased significantly to $(2.66M) for the quarter and $(3.06M) for the six months, compared to $(0.45M) and $(0.75M) in the prior year periods. This increase is primarily driven by higher operating expenses.
- Operating Expenses:
- R&D Expenses: Increased from $0 to $651,784 (quarter) due to the initiation of clinical trial activities and payroll.
- G&A Expenses: Increased from $427,757 to $2,012,120 (quarter). The surge is largely attributed to $1.45M in stock-based compensation and increased professional services.
- Liquidity: Cash balance increased from $3,455 (Dec 31, 2024) to $8.7M (June 30, 2025), driven by $11.9M in net IPO proceeds.
- Debt: Convertible notes totaling approximately $660,000 principal plus accrued interest were automatically converted into 297,133 shares of common stock upon the IPO closing.
Outlook, Risks, and Management Commentary
- Liquidity Outlook: Management believes current cash resources, bolstered by the IPO, are sufficient to fund operations for at least the next twelve months.
- Future Losses: The company expects to continue incurring substantial losses as it advances clinical trials and seeks FDA approval for Apitox.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of June 30, 2025. Material weaknesses were identified, including a lack of documented procedures for journal entries, segregation of duties, and reconciliations.
- Regulatory Risk: Success is dependent on obtaining FDA approval. The company has completed a positive Phase 3 trial for osteoarthritis but has not yet received approval.
- Related Party Transactions: Significant debt and advances were held by related parties (Apimeds Korea, Inscobee), though most convertible debt was converted to equity during the period.
Investor Verification Checklist
- Internal Control Remediation: Verify the specific plan and timeline to address the material weaknesses in internal controls over financial reporting.
- Cash Burn Rate: Monitor the rate of cash consumption against the $8.7M cash balance to confirm the 12-month runway projection.
- Stock-Based Compensation: Review the valuation assumptions (volatility, term) used for the significant stock grants ($1.7M in the quarter) and their impact on future dilution.
- Regulatory Milestones: Track the status of the FDA application for Apitox following the Phase 3 trial completion.
- Related Party Agreements: Review the terms of the license agreement with Apimeds Korea, specifically the 5% royalty on earnings before interest and taxes.